Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”
- Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity PITTSBURGH, April 23, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that its abstract on LP-10 for the treatment of Oral Lichen Planus (OLP) has been accepted for podium presentation at the 2025 joint international meeting of the American Academy of Oral Medicine (AAOM) and European Association of Oral Medicine (EAOM). The meeting will take place May 14–17 in Las Vegas.
- 04/23/2025
|
Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”
- Listen: PITTSBURGH, April 23, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
- 04/23/2025
|
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
- Listen: PITTSBURGH, April 22, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.
- 04/22/2025
|
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
- Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement PITTSBURGH, April 22, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.50 mg) of its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10, for the treatment of oral lichen planus (OLP). The Company also recently reported full enrollment across all three planned dose cohorts.
- 04/22/2025
|
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
- Topline Results Expected Q2 2025 Listen: PITTSBURGH, April 08, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
- 04/08/2025
|
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
- PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The Phase 2a trial has now fully enrolled participants across all three dose cohorts (0.25 mg, 0.50 mg and 1.0 mg of tacrolimus) at seven U.S. study sites.
- 04/08/2025
|
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast
- Episode titled “From Medicine to Biotech Innovation” now available PITTSBURGH, March 31, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced that Co-Founder and Chief Medical Officer Dr.
- 03/31/2025
|
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast
- PITTSBURGH, March 31, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced that Co-Founder and Chief Medical Officer Dr. Michael Chancellor is featured in the latest episode of The Pharmaverse Podcast, hosted by pharmaceutical industry executive recruiter Michael Pietrack. The episode, titled “From Medicine to Biotech Innovation,” offers an inside look at Dr. Chancellor's journey from clinical medicine to biotech leadership.
- 03/31/2025
|
Spartan Capital Securities, LLC Announces Key February Transactions
- New York, NY, March 07, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is pleased to announce a series of strategic transactions completed in February 2025, reinforcing its position as a trusted financial partner for companies across diverse industries.
- 03/07/2025
|
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement
- New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of a $3,788,000 private placement for Lipella Pharmaceuticals Inc. (Nasdaq: LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in this private offering.
- 03/04/2025
|
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
- PITTSBURGH, Feb. 11, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
- 02/11/2025
|
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
- LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today shared topline analysis of its Phase 2a multicenter dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus (“OLP”).
- 02/11/2025
|
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
- PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP). LP-310 is an innovative, localized therapy formulated to provide targeted relief for OLP patients while minimizing systemic exposure.
- 02/06/2025
|
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
- PITTSBURGH, February 6, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S.
- 02/06/2025
|
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement
- New York, NY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of two private placements for Lipella Pharmaceuticals Inc. (Nasdaq: LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in these private offerings of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc., raising an aggregate total of $875,500 through the transactions.
- 01/10/2025
|
Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions
- New York, NY, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is proud to announce a series of notable transactions completed in December 2024, further solidifying its reputation as a trusted partner for fast-growing companies across diverse industries.
- 12/31/2024
|
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement
- New York, NY, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities LLC, a premier investment banking firm, is pleased to announce the successful completion of a private placement for Lipella Pharmaceuticals Inc.'s (Nasdaq: LIPO) Spartan Capital Securities, LLC acted as the sole placement agent in the private offer and sale of up to 6,000,000 of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc. Lipella Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, successfully raised $1,722,000 through this private placement.
- 12/18/2024
|
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
- Peer-reviewed article highlights potential treatment for OLP with focus on localized drug delivery PITTSBURGH, Dec. 03, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, today announced the publication of a peer-reviewed paper in CUREUS.
- 12/03/2024
|
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
- PITTSBURGH, November 21, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
- 11/21/2024
|
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
- PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). In this first cohort, eight participants received a dose of 0.25 mg LP-310, with promising initial results.
- 11/21/2024
|
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
- PITTSBURGH, November 12, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S.
- 11/12/2024
|
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
- PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office (USPTO) on November 12, 2024.
- 11/12/2024
|
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
- PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company's certificate of incorporation with the Secretary of State of the State of Delaware.
- 11/01/2024
|
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
- PITTSBURGH, PA, November 1, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
- 11/01/2024
|
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
- PITTSBURGH, Pa., Oct. 29, 2024 – PRISM MediaWire – Lipella Pharmaceuticals, Inc.
- 10/29/2024
|
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
- PITTSBURGH, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Spartan Capital Investor Conference that is being held on November 4, 2024, at the Pierre Hotel in New York. Event: Lipella Presentation - 2024 Spartan Capital Investor Conference Date: Monday, November 4th, 2024 Time: 9:25 am EST Jonathan Kaufman will be available for one-on-one meetings with registered investors of the conference.
- 10/29/2024
|
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
- PITTSBURGH, PA, October 15, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing therapies for serious diseases with unmet medical needs, today announced the receipt of a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform.
- 10/15/2024
|
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
- Patent application covers key technology innovations for delivering therapeutic agents Proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing therapies for serious diseases with unmet medical needs, today announced the receipt of a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform. The patent application, U.S. Patent No.
- 10/15/2024
|
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
- PITTSBURGH, Oct. 09, 2024 – PRISM MediaWire – Lipella Pharmaceuticals, Inc.
- 10/09/2024
|
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
- PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024.
- 10/09/2024
|
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
- NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO).
- 09/25/2024
|
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
- PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP).
- 09/24/2024
|
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
- Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway Pittsburgh, PA, August 27, 2024 – Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C.
- 08/27/2024
|
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
- Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth.
- 08/22/2024
|
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
- Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth No FDA-approved therapy currently exists for OLP Patient registry and OLP study information is now available PITTSBURGH, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth.
- 08/22/2024
|
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
- Pittsburgh, PA, August 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing interstitial cystitis and detecting bladder cancer at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan, taking place August 21-23, 2024.
- 08/21/2024
|
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
- LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancer Novel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and Kidney Diseases 5 th International Consultation on Interstitial Cystitis Japan runs Aug. 21-23 in Kyoto PITTSBURGH, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing interstitial cystitis and detecting bladder cancer at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan, taking place August 21-23, 2024. LP-20, which has completed preclinical and proof-of-concept human trials, is administered via catheter into the bladder.
- 08/21/2024
|
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
- Top Line Data Expected Year-End 2024 Pittsburgh, August 12, 2024 — Lipella Pharmaceuticals Inc.
- 08/12/2024
|
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
- PITTSBURGH, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” “we” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients. Lipella's Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects experiencing symptomatic Oral Lichen Planus, a chronic inflammatory condition that affects mucous membranes in the mouth and causes burning and pain as well as white patches, swollen tissue or open sores.
- 08/12/2024
|
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
- PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc.
- 08/01/2024
|
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
- PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc.
- 08/01/2024
|
Why Is Lipella Pharmaceuticals (LIPO) Stock Up 149% Today?
- Lipella Pharmaceuticals (NASDAQ: LIPO ) stock is flying higher on Monday after the company presented investors with an update on its Phase 2a clinical trial evaluating LP-310. This is the company's drug candidate for the treatment of Oral Lichen Planus ( OLP ).
- 07/29/2024
|
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
- Top Line Data Expected Year-End 2024 Pittsburgh, July 29, 2024 — Lipella Pharmaceuticals Inc.
- 07/29/2024
|
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
- PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). This chronic inflammatory condition, which affects over 6 million Americans, is characterized by mouth mucous membrane inflammation, pain, and ulceration, and lacks FDA-approved treatments.
- 07/29/2024
|
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
- Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, PA., May 31, 2024 — Lipella Pharmaceuticals Inc.
- 05/31/2024
|
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
- Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evaluating LP-310 in the treatment of Oral Lichen Planus (OLP). With clearance received from the central Institutional Review Board (IRB), the Phase 2a trial is set to commence with site qualifications completed and patient recruitment underway.
- 05/31/2024
|
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Abstract highlighting new preclinical data from LP-50 in non-muscle invasive bladder cancer PITTSBURGH, Pa., May 29, 2024 – Lipella Pharmaceuticals Inc.
- 05/29/2024
|
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces an abstract publication at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, taking place from May 31 - June 4 in Chicago, IL, and online. Lipella's abstract, titled “Intravesical Administration of Pembrolizumab for Bladder Tumor- A Potential Strategy to Minimize Drug Toxicity” highlights new preclinical results from LP-50 (intravesical pembrolizumab) in induced murine non-muscle invasive bladder cancer (NMIBC).
- 05/29/2024
|
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
- Company to initiate Phase 2b clinical trial in lead asset, LP-10 in 2H 2024 Pittsburgh, PA, May 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration (“FDA”) Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program.
- 05/21/2024
|
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
- PITTSBURGH, May 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration (“FDA”) Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately 36 patients in the second half of 2024.
- 05/21/2024
|
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
- The new oncology committee will include: Jason Hafron, MD, DDS, PhD, MPH; and Pradeep Tyagi, PhD, MBA Pittsburgh, PA, April 17, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the expansion of its Scientific Advisory Board to include oncology expertise.
- 04/17/2024
|
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
- PITTSBURGH, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the expansion of its Scientific Advisory Board to include oncology expertise.
- 04/17/2024
|
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
- Pittsburgh, PA, April 05, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois.
- 04/05/2024
|
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
- PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella,” “our”, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois. Lipella's abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at www.asco.org/abstracts.
- 04/05/2024
|
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
- Pittsburgh, PA, April 03, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the U.S.
- 04/03/2024
|
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
- PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type C meeting request to discuss the company's proposed Phase-2b clinical trial design for the evaluation of LP-10, an intravesical liposomal formulation of tacrolimus, as a potential treatment for moderate to severe hemorrhagic cystitis (HC). Lipella expects to meet with the FDA on May 21, 2024.
- 04/03/2024
|
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
- Clinical testing of LP-410 expected to commence in Q2 2024 Pittsburgh, PA, March 05, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S.
- 03/05/2024
|
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
- PITTSBURGH, March 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for clinical testing of LP-410 in the treatment of oral Graft-Versus-Host Disease (GVHD). Lipella's clinical study, titled, A Multicenter, Dose-Ranging Trial Evaluating the Safety, Tolerability, and Efficacy of LP-410 in Subjects with Symptomatic Oral GVHD, is expected to commence in the second half of 2024.
- 03/05/2024
|
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
- Chief Medical Officer Dr. Michael Chancellor will discuss hemorrhagic cystitis and the company's lead candidate, LP-10 Pittsburgh, PA, February 20, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”) a pioneering, clinical-stage pharmaceutical company, announced today that Chief Medical Officer Dr.
- 02/20/2024
|
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
- PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, announced today that Chief Medical Officer Dr. Michael Chancellor will present at the PropThink Digital Investor Conference's key opinion leader (KOL) discussion on Friday, February 23, 2024, at 2 PM ET. Dr. Chancellor's presentation will be titled: “Urologist Talks Bladder Cancer and Lasting Side Effects”.
- 02/20/2024
|
PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success
- New York, December 20, 2023 – Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is celebrating a year of strategic accomplishments on its first anniversary as a public company. Lipella is advancing three clinical indications and has been granted two Orphan Drug Designations by the US Food and Drug Administration (FDA).
- 12/20/2023
|
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
- –Lipella Granted Two Orphan Drug Designations by FDA- Pittsburgh, PA, December 20, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”) a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity.
- 12/20/2023
|
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
- PITTSBURGH, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the Company has made substantial strides over the past year, achieving critical milestones and advancing its pipeline with three clinical indications and two orphan drug designations granted.
- 12/20/2023
|
Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug
- “GvHD affects approximately 30,000 Americans and oral GvHD causes significant oral pain and discomfort, making it difficult for patients to eat, drink and speak. Oral GvHD is a great unmet need in cancer survivors.
- 11/10/2023
|
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease
- Lipella Pharmaceuticals' LP-310 clinical stage asset is formulated for delivering active agents to the oral cavity for diseases of the mouth including oral lichen planus and oral graft-versus-host disease PITTSBURGH , Nov. 10, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical stage pharmaceutical company addressing serious diseases with significant unmet need based in Pittsburgh, PA, announced today that it has been granted "Orphan Drug Designation" from the U.S. Food and Drug Administration (FDA) for its drug candidate, LP-310, which has been designed for the treatment of oral Graft-versus-Host Disease (GvHD). FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease LP-310 is Lipella's clinical stage pipeline asset intended to be indicated for inflammatory diseases of the oral cavity, including oral lichen planus and oral GvHD.
- 11/10/2023
|
Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference
- Pittsburgh, PA, October 23, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, will present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference to be held from October 24th – 27th. Dr.
- 10/23/2023
|
Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment
- Shares of Lipella Pharmaceuticals Inc. LIPO, +51.55% rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology company's investigational new drug application for its oral lichen planus treatment was approved by the U.S. Food and Drug Administration. Trading volume in the stock, which was the best performer on the major U.S. exchanges, blasted higher to 30.7 million shares, compared with the full-day average of about 6,400 shares.
- 10/20/2023
|
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus
- LP-310 is an oral formulation of Lipella's lead asset LP-10. PITTSBURGH , Oct. 20, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for a multi-center, phase-2a, dose-escalation clinical trial to assess the safety and efficacy of LP-310 in patients with symptomatic oral lichen planus (OLP), a highly morbid condition with no effective treatment.
- 10/20/2023
|
How News Impacts Your Penny Stocks Portfolio
- Use these tips for investing in penny stocks in 2023 The post How News Impacts Your Penny Stocks Portfolio appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/17/2023
|
Penny Stocks To Buy? 4 To Watch Now After Big News
- Penny stocks to watch after big news this week The post Penny Stocks To Buy? 4 To Watch Now After Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/16/2023
|
